Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (5), 4655-4660

IL-32 Expression Indicates Unfavorable Prognosis in Patients With Colon Cancer

Affiliations

IL-32 Expression Indicates Unfavorable Prognosis in Patients With Colon Cancer

Jing-Ming Zhai et al. Oncol Lett.

Abstract

Recently, interleukin (IL)-32 has been demonstrated to represent a novel biomarker for evaluating the prognosis of patients with gastric and lung cancer; however, its clinical significance in colon cancer remains unknown. In the present study, the IL-32 expression in 60 patients with colon cancer was examined with an immunohistochemistry assay. IL-32 expression was determined in 37 (61.67%) patients with colon cancer. Additionally, IL-32 was associated with tumor size and Dukes' stage. By using the Kaplan-Meier method, patients with positive IL-32 expression had shorter overall survival time, compared with those with negative IL-32 expression. Multivariate analysis indicated that IL-32 could be an independent prognostic factor in patients with colon cancer; therefore, IL-32 may be a novel prognostic biomarker and therapeutic target for colon cancer.

Keywords: colon cancer; interleukin-32; prognosis.

Figures

Figure 1.
Figure 1.
Immunohistochemical staining of IL-32 in non-cancerous colon and colon cancer tissues. (A) IL-32 staining was weak in non-cancerous colon tissues (magnification, ×100). (B) IL-32 staining was weak in non-cancerous colon tissues (magnification, ×200). (C) Positive IL-32 expression was exhibited in colon cancer tissues (magnification, ×100). (D) Positive IL-32 expression was exhibited in colon cancer tissues (magnification, ×200). IL, interleukin.
Figure 2.
Figure 2.
Expression levels of IL-32 protein in colon cancer and paired non-cancerous tissues determined with western blot analysis. C1-5 refers to patient/cases 1–5. C, cancer tissues; N, non-cancerous tissues; IL, interleukin.
Figure 3.
Figure 3.
Immunohistochemical staining of IL-32 and Ki-67 in the same patient. (A) Positive IL-32 expression in colon cancer (magnification, ×100). (B) Positive IL-32 expression in colon cancer (magnification, ×200); (C) Positive Ki-67 expression in colon cancer (magnification, ×100). (D) Positive Ki-67 expression in colon cancer (magnification, ×200).
Figure 4.
Figure 4.
Survival analyses according to Kaplan-Meier methods.

Similar articles

See all similar articles

LinkOut - more resources

Feedback